Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis

Table 4 Comparison of all lupus nephritis treatments for fertility issues (amenorrhea or ovarian failure)

Treatment	Reference	OR (95 % CrI)	RR (95 % CrI)	RD % (95 % Crl)
CYC	PRED	3.81 (1.26, 14.31)	2.64 (1.18, 7.51)	0.25 (0.04, 0.47)
MMF		0.48 (0.09, 3.04)	0.52 (0.11, 2.58)	−0.07 (−0.23, 0.13)
AZA		2.74 (0.26, 28.27)	2.12 (0.30, 8.18)	0.17 (−0.15, 0.65)
CYC LD		9.06 (0.63, 121.50)	3.79 (0.68, 11.71)	0.45 (−0.06, 0.81)
MMF	CYC	0.13 (0.03, 0.41)	0.20 (0.05, 0.56)	−0.31 (−0.47, −0.16)
AZA		0.69 (0.09, 5.08)	0.79 (0.14, 1.95)	−0.08 (−0.37, 0.36)
CYC LD		2.23 (0.23, 23.20)	1.46 (0.34, 2.71)	0.19 (−0.27, 0.55)
AZA	MMF	5.25 (0.78, 54.39)	3.68 (0.81, 19.08)	0.22 (−0.02, 0.68)
CYC LD		16.35 (1.97, 247.70)	6.49 (1.72, 30.95)	0.50 (0.06, 0.87)
CYC LD	AZA	3.20 (0.55, 21.24)	1.69 (0.68, 6.12)	0.22 (−0.11, 0.60)
Random-effects model	Residual deviance	15.93 vs. 17 data points
	Deviance information criteria	72.233
Fixed-effects model	Residual deviance	16.16 vs. 17 data points
	Deviance information criteria	72.069

Based on eight RCTs with 839 patients: seven two-arm trials and one three-arm trial
Significant odds ratios are in italics
For absolute rates for events used for calculation of risk difference, please see Appendix 6
OR odds ratio, RR relative risk, RD risk difference, CrI credible interval, HD high dose, LD low dose; when not specified, it indicates standard dose, CYC cyclophosphamide, MMF mycophenolate mofetil, CSA cyclosporine, TAC tacrolimus, LEF leflunomide, PRED prednisone, prednisolone or methylprednisolone, AZA azathioprine, RTX rituximab
The odds ratios were transformed to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients

ISSN: 2046-4053